Journal
ARCHIVES OF PHARMACAL RESEARCH
Volume 38, Issue 3, Pages 414-422Publisher
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-015-0570-2
Keywords
Cancer stem cells; Tumor initiating cells; Chemo-resistance; Radio-resistance; Recurrence
Categories
Funding
- National Research Foundation of Korea - Korea government (MSIP) [2011-0030074, 2011-0023431, 2012-M3A9B6055466]
- National Research Foundation of Korea [2011-0023431, 2011-0030074] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Several decades after the first notion that cancer cells are heterogeneous, not only histologically but also at the level of tumorigenicity, the existence of a tumor initiation population (so-called cancer stem cells) is now widely accepted. Here, we review the historical background leading up to the identification of this special cancer cell population and its role in the resistance of tumors to conventional therapies. In addition, we briefly review the clinical targeting strategy of the specific signaling network for cancer stem cells. Current clinical trials with newly developed drugs or older drugs for other uses are summarized to provide an understanding of the current status of strategies to target cancer stem cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available